Key Takeaways
Protara Therapeutics’ TARA-002 showed a 55% complete response rate at 12 months in a study of patients with non-muscle invasive bladder cancer, setting the stage for a pivotal trial and positioning the therapy as a potential new option for patients who have not received prior BCG treatment.
"The NMIBC patient community faces a critical unmet need for safe, effective and bladder-sparing treatment options for this devastating disease," said Mark Tyson, a professor of urology at Mayo Clinic Phoenix and an ADVANCED-2 study investigator. "These compelling data, coupled with a simple, streamlined administration for both physicians and patients, make TARA-002 a potentially important new treatment option for BCG-Naïve high risk NMIBC patients.”
The updated results from the Phase 2 ADVANCED-2 trial, presented at the American Urological Association 2026 Annual Meeting, showed an any-time complete response rate of 72.4% among 29 evaluable patients. The response rate was 66.7% at the six-month mark and 55% at 12 months. The therapy was well-tolerated, with no Grade 3 or greater treatment-related adverse events and no patient discontinuations due to such events.
The positive data could position TARA-002 as a strong competitor in the NMIBC market, which affects approximately 65,000 new patients in the U.S. annually. Protara plans to initiate a larger registrational trial, ADVANCED-3, in the second half of 2026, a key step toward potential FDA approval and commercialization.
The ADVANCED-2 study evaluated TARA-002, an investigational cell therapy derived from Streptococcus pyogenes, in patients with high-risk NMIBC who had not previously been treated with the standard immunotherapy, Bacillus Calmette-Guérin (BCG). The durability of the response was a key finding, with a Kaplan-Meier estimate showing a 73.1% probability of maintaining a complete response for six months.
The safety profile reinforces the therapy's potential. The most common treatment-related adverse events were mild and transient, including dysuria, fatigue, and hematuria. This favorable safety is critical in a patient population often facing therapies with significant side effects.
Protara Therapeutics is now focused on the next steps for TARA-002. The company has completed enrollment for the BCG-Naïve cohort of the ADVANCED-2 trial and expects to complete enrollment for a separate cohort of BCG-Unresponsive patients in the second half of 2026.
The planned ADVANCED-3 registrational trial will compare TARA-002 to intravesical chemotherapy. Success in this trial would provide the evidence needed for regulatory submission. Analysts are optimistic, with a consensus "Strong Buy" rating and an average price target of $26.67, implying significant upside from its recent close of $5.32, according to TipRanks. LifeSci Capital reiterated a "Buy" rating with a $26.00 price target following the data release.
This article is for informational purposes only and does not constitute investment advice.
